Company Overview
Company Type: Private Company
Website: signalchemlifesciences.com
Number of Employees: -
Year Founded: 2004
Total Amount Raised (CAD mm)†: 20.00
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Signalchem Lifesciences Corporation develops and produces cellular signaling proteins and enzymes. It offers enzymes, extracellular ligands, signaling proteins, signaling reagents, and antibodies. The company also provides discovery services, such as custom protein development and compound selectivity profiling services. It serves scientists in basic research and drug discovery. The company offers its products through distributors in Belgium, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, India, Ireland, Italy, Japan, Korea, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Portugal, the Slovak Republic, Spain, Sweden, Switzerland, Taiwan, the United Kingdom, the United States; and online. The company was founded in 2004 and is based in Richmond, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Sanghera, Jasbinder
Chief Executive Officer and President
Zilinsky, Darren
Chief Financial Officer

Key Board Members
Name
Title
Fabbro, Doriano 
Member of Scientific Advisory Board
Lang, Marc 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
13120 Vanier Place | Richmond, BC | V6V 2J2 | Canada
Phone: 604 232 4600   Fax: 604 232 4601


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-17-2022
-
Private Placement
Target
Signalchem Lifesciences Corporation


15.75
May-20-2021
Cancelled
Merger/Acquisition
Buyer
Newmac Resources Inc. (TSXV:NER)
Signalchem Lifesciences Corporation
Real Flourish Holdings Limited,0979595 BC Ltd
-
Jul-18-2012
Cancelled
Merger/Acquisition
Buyer
International Gold Corp.
Signalchem Lifesciences Corporation
Woodburn Holdings Ltd.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-07-2022
M&A Transaction Cancellations
SignalChem Lifesciences Corporation cancelled the acquisition of Newmac Resources Inc. (TSXV:NER) from 0979595 BC Ltd, Real Flourish Holdings Limited and others in a reverse merger transaction.
Feb-17-2022
Private Placements
Signalchem Lifesciences Corporation announced that it expects to receive CAD 20.000001 million in funding
Sep-23-2021
Client Announcements
Xuanzhu Biopharmaceutical Co., Ltd. and Signalchem Lifesciences Corporation Enters into Collaboration and Licensing Agreement for the Development and Commercialization Interests of SLC-391
May-20-2021
M&A Transaction Announcements
SignalChem Lifesciences Corporation entered into a letter of intent to acquire Newmac Resources Inc. (TSXV:NER) in a reverse merger transaction.
Mar-31-2021
Company Conference Presentations
SignalChem Lifesciences Corporation Presents at Spring 2021 Oncology Investor Conference, Mar-31-2021 11:10 AM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 11:21 PM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Sep 14, 2023 09:31 PM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp
Reports
38
GlobalData

Jun 16, 2023 03:00 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp
Reports
38
GlobalData

Jun 09, 2023 05:49 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Mar 16, 2023 03:47 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp
Reports
38
GlobalData

Mar 10, 2023 03:59 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Dec 14, 2022 07:57 PM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp
Reports
38
GlobalData

Dec 10, 2022 02:50 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Sep 23, 2022 07:01 PM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp
Reports
37
GlobalData

Sep 15, 2022 04:51 AM
Signalchem Lifesciences Corporation
SignalChem Lifesciences Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Fabbro, Doriano 
Member of Scientific Advisory Board
604 232 4600
604 232 4601

Lang, Marc 
Member of Scientific Advisory Board
604 232 4600
604 232 4601

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Sanghera, Jasbinder
Chief Executive Officer and President
604 232 4600
604 232 4601
jsanghera@metasignal.ca
Zilinsky, Darren
Chief Financial Officer
604 232 4600
604 232 4601
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
